勘误：玻璃体内注射阿柏西普治疗与脉络膜视网膜炎相关的脉络膜新生血管：一项初步研究[勘误]
Erratum: Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study [Corrigendum].
出版信息
Clin Ophthalmol. 2017 Aug 28;11:1567. doi: 10.2147/OPTH.S148326. eCollection 2017.
Abstract
[This corrects the article on p. 1315 in vol. 11, PMID: 28769551.].
摘要
[这纠正了第11卷第1315页上的文章， PMID: 28769551。]
相似文献
1
Erratum: Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study [Corrigendum].勘误：玻璃体内注射阿柏西普治疗与脉络膜视网膜炎相关的脉络膜新生血管：一项初步研究[勘误]
Clin Ophthalmol. 2017 Aug 28;11:1567. doi: 10.2147/OPTH.S148326. eCollection 2017.
2
Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study.玻璃体内注射阿柏西普治疗与脉络膜视网膜炎相关的脉络膜新生血管：一项试点研究。
Clin Ophthalmol. 2017 Jul 20;11:1315-1320. doi: 10.2147/OPTH.S132923. eCollection 2017.
3
Erratum: A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum].勘误：一项由研究者发起的单臂研究，评估玻璃体内注射阿柏西普对曾接受雷珠单抗或贝伐单抗治疗的渗出性年龄相关性黄斑变性患者的疗效、安全性及耐受性（ASSESS研究）：12个月分析 [更正]
Clin Ophthalmol. 2017 Feb 7;11:303. doi: 10.2147/OPTH.S116038. eCollection 2017.
4
Corrigendum.勘误
Paediatr Child Health. 2015 Nov-Dec;20(8):466-7. doi: 10.1093/pch/20.8.466.
5
Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study.玻璃体内注射阿柏西普治疗病理性近视相关性脉络膜新生血管：一项初步研究。
Clin Ophthalmol. 2016 Nov 4;10:2223-2229. doi: 10.2147/OPTH.S117791. eCollection 2016.
6
Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization.玻璃体内阿柏西普与贝伐单抗治疗近视性脉络膜新生血管。
Sci Rep. 2018 Sep 26;8(1):14389. doi: 10.1038/s41598-018-32761-z.
7
Erratum: Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab [Corrigendum].勘误：阿柏西普用于之前使用雷珠单抗良好控制的新生血管性年龄相关性黄斑变性患者后解剖学结局恶化 [勘误]
Clin Ophthalmol. 2017 Feb 16;11:355. doi: 10.2147/OPTH.S133223. eCollection 2017.
8
Aflibercept efficacy in refractory choroidal neovascularization.阿柏西普治疗难治性脉络膜新生血管的疗效
Rom J Ophthalmol. 2016 Apr-Jun;60(2):96-102.
9
Erratum: Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion [Corrigendum].勘误：日本视网膜分支静脉阻塞继发黄斑水肿患者从雷珠单抗转换为阿柏西普治疗后注射间隔时间的延长 [勘误]
Clin Ophthalmol. 2017 Apr 5;11:619. doi: 10.2147/OPTH.S136670. eCollection 2017.
10
Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis.贝伐单抗用于治疗念珠菌性脉络膜视网膜炎继发的脉络膜新生血管形成。
Int Ophthalmol. 2018 Apr;38(2):781-785. doi: 10.1007/s10792-017-0502-x. Epub 2017 Mar 30.
Zotero 插件